Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9H1R2

UPID:
DUS15_HUMAN

ALTERNATIVE NAMES:
VH1-related member Y; Vaccinia virus VH1-related dual-specific protein phosphatase Y

ALTERNATIVE UPACC:
Q9H1R2; A6NH79; A8MVC8; Q5QP62; Q5QP63; Q5QP65; Q6PGN7; Q8N826; Q9BX24

BACKGROUND:
The Dual specificity protein phosphatase 15, known for its alternative names VH1-related member Y and Vaccinia virus VH1-related dual-specific protein phosphatase Y, is a key player in cellular signaling. It has been identified to dephosphorylate several important proteins including MAPK13 and ERBB3, indicating its broad impact on cell function. Additionally, its potential role in oligodendrocyte differentiation and myelin formation highlights its importance in neural health.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Dual specificity protein phosphatase 15 offers a promising pathway to developing novel therapeutic strategies. Given its involvement in critical signaling pathways and neural development, targeting this protein could lead to breakthroughs in treating a range of neurological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.